Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-positive breast cancer with liver metastases
CTR20220140Phase 2Completed
- Sponsor
- Hangzhou Miracogen
- Start
- Jan 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002 in breast cancer, sponsored by Hangzhou Miracogen. Started Jan 2022; status: completed.
02
Drugs
MRG002
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20220140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220140.